Next Article in Journal
Interactions between Inhibitors and 5-Lipoxygenase: Insights from Gaussian Accelerated Molecular Dynamics and Markov State Models
Previous Article in Journal
Kuwanon C Inhibits Tumor Cell Proliferation and Induces Apoptosis by Targeting Mitochondria and Endoplasmic Reticulum
Previous Article in Special Issue
The Tumor Microenvironment Mediates the HIF-1α/PD-L1 Pathway to Promote Immune Escape in Colorectal Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 15
10.3390/ijms25158294
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Gastric Carcinogenesis and Potential Role of the Transient Receptor Potential Vanilloid 1 (TRPV1) Receptor: An Observational Histopathological Study

by
Sylvester R. Groen
1,
Daniel Keszthelyi
1,*,
Arpad Szallasi
2,
Jara A. van Veghel
1,
Annick M. E. Alleleyn
1,
Kata Csekő
3,4,5,
Zsuzsanna Helyes
3,4,5,
Iryna Samarska
6,
Heike I. Grabsch
6,7,
Ad A. M. Masclee
1 and
Zsa Zsa R. M. Weerts
1
1
Department of Gastroenterology and Hepatology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, 6629 HX Maastricht, The Netherlands
2
Department of Pathology and Experimental Cancer Research, Semmelweis University, 1083 Budapest, Hungary
3
Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary
4
HUN-REN Chronic Pain Research Group, University of Pécs, 7624 Pécs, Hungary
5
National Laboratory for Drug Research and Development, 1117 Budapest, Hungary
6
Department of Pathology, Maastricht University Medical Center+, 6629 HX Maastricht, The Netherlands
7
Division of Pathology and Data Analytics, Leeds Institute of Medical Research at St James’s University, University of Leeds, Leeds LS2 9JT, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(15), 8294; https://doi.org/10.3390/ijms25158294 (registering DOI)
Submission received: 10 July 2024 / Revised: 26 July 2024 / Accepted: 26 July 2024 / Published: 30 July 2024
(This article belongs to the Special Issue Advanced Research on Biomarkers in Gastrointestinal Cancer 2.0)
Browse Figures
Review Reports Versions Notes

Abstract

:
The potential role of the transient receptor potential Vanilloid 1 (TRPV1) non-selective cation channel in gastric carcinogenesis remains unclear. The main objective of this study was to evaluate TRPV1 expression in gastric cancer (GC) and precursor lesions compared with controls. Patient inclusion was based on a retrospective review of pathology records. Patients were subdivided into five groups: Helicobacter pylori (H. pylori)-associated gastritis with gastric intestinal metaplasia (GIM) (n = 12), chronic atrophic gastritis (CAG) with GIM (n = 13), H. pylori-associated gastritis without GIM (n = 19), GC (n = 6) and controls (n = 5). TRPV1 expression was determined with immunohistochemistry and was significantly higher in patients with H. pylori-associated gastritis compared with controls (p = 0.002). TRPV1 expression was even higher in the presence of GIM compared with patients without GIM and controls (p < 0.001). There was a complete loss of TRPV1 expression in patients with GC. TRPV1 expression seems to contribute to gastric-mucosal inflammation and precursors of GC, which significantly increases in cancer precursor lesions but is completely lost in GC. These findings suggest TRPV1 expression to be a potential marker for precancerous conditions and a target for individualized treatment. Longitudinal studies are necessary to further address the role of TRPV1 in gastric carcinogenesis.

1. Introduction

Gastric cancer (GC) is the fifth most common cancer worldwide and is associated with significant cancer-related mortality [1,2]. Once GC has metastasized, the patient’s prognosis is poor. However, early diagnosis and treatment significantly increase patient survival [3]. Detection of early-stage GC bares difficulties due to a complex interaction of pathophysiological pathways and endo- and exogenous factors [4,5]. Chronic inflammation of the gastric mucosa can lead to the development of chronic atrophic gastritis (CAG), characterized by loss of specialized gastric glands, mucosal fibrosis and gastric intestinal metaplasia (GIM), a recognized precancerous lesion [6,7]. A major contributing factor is inflammation caused by Helicobacter pylori (H. pylori), especially when left untreated. In large epidemiologic studies, up to 3.0% of patients suffering from H. pylori-associated gastritis developed gastric carcinoma [8,9,10].
The potential role of dietary capsaicin (the bioactive pungent component of chili peppers) in GC development has long been subject to scientific debate [11,12,13], with no convincing evidence linking habitual capsaicin consumption to GC. However, some studies have suggested that chronic exposure or single high-dose capsaicin (30–60 milligrams per day) can induce gastric mucosal injury and (chronic) inflammation [14,15,16], whereas other studies suggested that capsaicin (particularly in lower doses corresponding to daily use) and its natural homologs and analogs (capsaicinoids) can prevent gastric mucosal damage related to alcohol and non-steroidal anti-inflammatory drugs and, therefore, may prevent gastric carcinogenesis [17,18].
Given the potential role of capsaicin in gastric carcinogenesis, specific interest has been directed in recent studies toward its target, the transient receptor potential Vanilloid 1 (TRPV1) receptor [19,20,21], although non-TRPV1-mediated effects of capsaicin have also been described [22]. The TRPV1 receptor is a calcium-permeable non-selective cation channel belonging to the transient receptor potential (TRP) cation channel family and is predominantly localized in extrinsic sensory fibers of the gastrointestinal tract and non-neuronal cells such as gastric epithelial cells [23,24]. TRPV1 receptor activation leads to the alterations of intracellular calcium concentrations, inducing the release of several neuropeptides from sensory nerve endings, exerting vascular smooth muscle action, inflammatory cell proliferation and plasma protein extravasation, which suppress gastric acid production and may prevent apoptosis and oxidative stress [25,26].
Regarding carcinogenesis, the involvement of TRPV1 as a tumor suppressor has been described in various carcinogenic pathways, including breast cancer, urothelial cell carcinoma and thyroid cancer [27,28]. However, the upregulation of TRPV1 in colonic cancer and esophageal squamous cancer correlates with tumor progression, migration, and poor survival [29,30]. In contrast, in vitro (over)expression of TRPV1 in mouse models of GC resulted in the inhibition of tumor proliferation, migration, tissue invasion and smaller tumor size. Others have found less peritoneal dissemination in TRPV1-depleted mice [31,32]. In human GC cells, a significant decrease in TRPV1 expression was described, suggesting TRPV1 to be a potential marker for the prognosis of GC due to its correlation with GC progression [33,34]. Considering the current literature, the role of TRPV1 expression in gastric carcinogenesis remains unclear. The main objective of this observational study was to assess TRPV1 expression in the gastric mucosa in patients with H. pylori-associated gastritis with and without GIM, CAG and intestinal-type adenocarcinoma.

2. Results

2.1. Study Population and Samples

Fifty-five patients were included for analysis, of whom 31 (65.4%) were females. The median age was 60.4 (±16.3) years, and 58.2% had an age over 60 years. Patients were distributed into five groups: five patients were labeled as controls with normal stomach mucosa, 12 patients with H. pylori-associated gastritis with GIM, 13 patients with CAG with GIM, 19 patients with H. pylori-associated gastritis without GIM and six patients with gastric adenocarcinoma. In all patients, at least one stomach tissue sample was retrieved during biopsy for analysis and immunohistochemical staining. In most patients, gastric biopsies were retrieved from the antral and body region of the stomach (n = 52, 94.5% of total). In three patients, only cardia (n = 2) or angulus (n = 1) were sampled. All patient characteristics are provided in Table 1.

2.2. TRPV1 Expression Is Lost in Gastric Adenocarcinoma

After initial pathological examination, tissue samples underwent immunohistochemical staining for the assessment of TRPV1 immunopositivity (Figure 1A–D). In all tissue samples, the median immunoreactive score (IRS, paragraph 4.3 of the materials and methods section) was calculated to quantify TRPV1 expression, as outlined in Table 2. Additionally, a median IRS was calculated for each group of all cells combined (foveolar cells, parietal cells and chief cells). In parietal cells, the TRPV1 expression was generally higher in all groups. In foveolar cells of gastric tissue retrieved from controls, there was no TRPV1 expression; therefore, no median IRS could be calculated. In tissue samples identified as gastric adenocarcinoma, there was no TRPV1 expression in either foveolar cells, parietal cells or chief cells.

2.3. TRPV1 Expression Significantly Higher in GIM Compared with No GIM or Controls

Between all groups, there were significant differences in TRPV1 expression, in which a significantly greater TRPV1-immunopositivity was found in patients with GIM compared with patients without GIM and controls (Table 2). Similar results were seen when all cells were combined to calculate a mean IRS for each group (Figure 2A). This significant difference was confirmed using post hoc analysis, except for the inter-group difference of H. pylori versus GIM and CAG versus GIM (p = 0.13).

2.4. Significant Differences TRPV1 Expression within All Groups according to Cell Type

In controls, TRPV1 expression was significantly higher in parietal cells, followed by the TRPV1 expression in chief cells, and was the lowest in foveolar cells (F = 92.250, p < 0.002). Similar results were conducted within other groups, all statistically significant: H. pylori-associated gastritis with GIM (F = 12.123, p = 0.002), CAG with GIM (F = 10.583, p = 0.003), and H. pylori-associated gastritis without GIM (F = 9.534, p = 0.002). Post hoc analysis revealed the highest TRPV1 expression in parietal cells and the lowest in foveolar cells in all groups.

3. Discussion

In this observational histopathological study, TRPV1 expression was significantly higher in patients with H. pylori-associated gastritis compared with controls. When GIM was present, TRPV1 expression was even higher compared with patients without GIM, particularly in parietal cells. TRPV1 expression was completely absent in gastric adenocarcinoma.
The role of TRPV1 in various inflammatory and carcinogenic pathways has been previously studied with contradictory results, revealing both pro- and anti-inflammatory and tumor-promoting and -suppressing effects. Several studies have demonstrated an increase in TRPV1 expression in various inflammatory processes, in which downregulating the TRPV1 receptor by genetic manipulation or inhibiting with an antagonist contributed to alterations in disease activity and severity [1,4,35]. This effect was shown in animal studies addressing inflammatory bowel disease, demonstrating decreased inflammation and disease severity in TRPV1-depleted mice [24,36,37]. In the gastric mucosa, the tachykinin substance P and CGRP are released in response to TRPV1 activation, which triggers neurogenic inflammatory pathways with consecutive inflammatory cell activation [19,27,35]. H. pylori-induced gastric inflammation is associated with the upregulation of pro-inflammatory cytokines such as IL-6 and IFN-Ƴ, pathways in which the TRPV1 receptor activation can have a facilitating role [8,9,38]. On the other hand, other studies have shown that a nontoxic dose of capsaicin inhibited the H. pylori-induced IL-8 production by gastric epithelial cells through the modulation of I-κB-, NF-κB- and IL-8 pathways [15].
H. pylori-associated gastritis is known as an individual risk factor for the development of GC, especially when untreated [8]. The co-administration of high-dose capsaicin (30–60 milligrams/day) has shown a synergistic contribution to accelerated loss of differentiated gastric epithelial cell types, leading to precancerous conditions such as GIM and CAG [8,9,15,18]. The significant increase in TRPV1 expression in patients with H. pylori-associated gastritis compared with controls might be due to the pro-inflammatory roles of TRPV1. A pending knowledge gap remains: it is unclear whether H. pylori-associated gastritis leads to TRPV1 overexpression, thereby increasing the risk of gastric cancer, or if the secondary epithelial changes associated with TRPV1 expression result in (pre)malignant transformation. In addition, it remains to be established whether TRPV1-induced immune activation contributes to the further aggravation of H. pylori-gastritis or rather has mitigating effects. Future preclinical functional and prospective clinical research investigating the specific correlations of TRPV1 expression in H. pylori-associated gastritis and gastric carcinogenesis is needed.
A complete loss of TRPV1 expression in gastric adenocarcinoma was found in our study population. This is largely in line with findings as described by Gao et al., in which a decreased TRPV1 expression in human GC was seen compared with tumor-adjacent tissue [4]. This decrease was associated with tumor size, metastases and poor prognosis, suggesting a tumor suppressant role of TRPV1. The complete loss of TRPV1 in gastric carcinoma, as observed here, may imply a tumor suppressor role. Our study also showed a significantly higher TRPV1 expression in patients with GIM and CAG, both known as precancerous conditions [1,6]. The number of reports underlining the involvement of calcium-permeable TRP channels in GC development is increasing, showing either aberrant receptor expression or function leading to alterations in intracellular calcium levels [4,33,39]. Over the past two decades, several members of the TRP channel family besides TRPV1 have been identified in gastric carcinogenesis, including TRPV2/4/6, TRP Melastatin (TRPM) 2/5/7/8 and TRP Canonical (TRPC) 1/3/6 [25,40,41,42,43,44]. However, most of these receptors are associated with upregulation or overexpression in gastric cancer and have been suggested as oncogene and tumor promotors in GC. Furthermore, the expression of TRPV2, TRPV4 and TRPV6 was found to increase according to the tumor stage with an association with poor prognosis, particularly in advanced stages [4,40]. Additionally, the inhibition of various TRP channels, including TRPM2/8 and TRPV2/4, may suppress the progress of GC development. With regard to TRPV1, its activation leads to intracellular calcium increase and the activation of anti-oncogenic pathways, resulting in decreased expression of cyclin D1 and MMP2, among others. In line with this concept, the downregulation of TRPV1 expression in mice promoted GC cell proliferation, invasion and dissemination, suggesting a tumor suppressant role of TRPV1 [4]. In contrast, another study found that the upregulation of TRPV1 expression after the administration of a high dose of (dietary) capsaicin (30–60 milligrams/day) can accelerate GC metastasis [1]. Since there is significantly higher TRPV1 expression in patients with GIM or CAG compared with controls, the question arises whether this is due to a tumor-promoting effect eventually resulting in GC or a counterbalancing tumor-suppressant mechanism directed at mitigating the pro-cancerous processes. The eventual loss of TRPV1 expression is supportive of the latter notion. Hypothetically, TRPV1 expression could be considered a marker for precancerous conditions. Future longitudinal studies with serial assessment of TRPV1 staining as a part of surveillance endoscopies for gastric precancerous conditions could further clarify this issue. Moreover, it warrants further investigation to determine whether there is a relationship between capsaicin dose and its potential pro- or anti-carcinogenic effects and whether these effects are mediated by TRPV1-dependent mechanisms.
Due to the retrospective nature of this observational immunopathological study with a small sample size, there are several limitations to be noted. Since this study had a purely observational nature, no longitudinal patient follow-up was performed. Therefore, it remains uncertain whether patients with precursor stages of gastric cancer did or did not develop malignant neoplasms. Additional verification of the staining of the immonohistochemistry of the pathological preparations would clarify this further. In addition, no functional readouts were conducted. Although errors in the immunohistochemical staining process could have occurred, mostly leading to underestimating TRPV1 immunopositivity, a significant increase in TRPV1 expression was found. This effect could, therefore, be even more apparent when correcting for this bias.
In summary, this observational histopathological study is the first to address TRPV1 expression in precursor stages of GC and H. pylori-associated gastritis, which is an individual risk for GC development. Significantly increased TRPV1 expression was demonstrated in H. pylori-associated gastritis and was even greater in patients with GIM and CAG, but its complete loss was seen in GC. These findings point to a potential tumor-suppressive role of TRPV1 and suggest that TRPV1 expression is a potential biomarker for precancerous conditions and a putative novel target for individualized treatment. Future longitudinal clinical studies with follow-up of precursor stages of GC and those addressing the impact of TRPV1 agonists (e.g., capsaicin) should provide more insight into the exact role of TRPV1 in gastric carcinogenesis.

4. Materials and Methods

4.1. Study Design and Patient Selection

In this observational study, samples were selected based on a retrospective review of the pathology records of patients who underwent upper gastrointestinal (GI) endoscopy at Maastricht University Medical Center+ (MUMC+) in Maastricht, the Netherlands, between 2009 and 2017. Patient inclusion was based on a histopathological diagnosis, which was confirmed independently by two pathologists. Patients were subdivided into five groups based on pathologic diagnosis: H. pylori-associated gastritis without GIM, H. pylori infection-associated gastritis with GIM, CAG, adenocarcinoma (intestinal type carcinoma) and controls. In all patients, multiple biopsies were taken from the stomach according to the Sydney protocol, using standard biopsy forceps with a diameter of 2.8 mm (Boston Scientific, Marlborough, MA, USA). The initial indication for performing an upper GI endoscopy included upper GI symptoms (p.e. regurgitation, upper stomach pain), iron deficiency and anemia. Controls were selected from the pathological records of patients who underwent upper GI endoscopy to exclude celiac disease, in which multiple biopsies were taken in the stomach and duodenum. After excluding celiac disease and other gastric pathological conditions using histopathological evaluation as described earlier, patients were assigned to the control group.

4.2. Ethical Statement and Tissue Sampling

The study was approved by the Local Ethic Committee (METC number 16-4-012) of the Maastricht University Medical Center+ (MUMC+). After initial histopathological examination in MUMC+, human tissue samples were anonymized for secondary immunohistochemical assessment and securely shipped to the laboratory of the University of Pécs/Szentágothai Research Center in Pécs, Hungary. Tissue samples were digitalized after immunohistochemical staining in an anonymized electronic database.

4.3. TRPV1 Immunohistochemical Staining

Tissue samples were formalin-fixed and paraffin-embedded, and 5 µm sections were cut as part of a routine pathological specimen work-up. For secondary analysis of TRPV1 expression, tissue samples were deparaffinized, rehydrated and incubated in an acidic citrate buffer (pH = 6) in a microwave oven for antigen recovery. Endogenous peroxidase activity was quenched using 3% hydrogen peroxide. After sections were washed and incubated in a blocking solution, anti-TRPV1 antibodies were applied (GP14100; Neuromics, Edina, MN, USA). Slides were then incubated with an anti-rabbit antibody conjugated with the EnVision system with horse radish peroxidase (DakoCytomation, Carpinteria, CA, USA). To visualize the reaction, 3,3-diaminobenzide tetrachloride was used, followed by counterstaining with hematoxylin [45]. Validation of antibody selectivity was validated by the lack of immunopositivity after the application of the blocking peptide (Neuromics, Edina, MN, USA) based on previous studies [46].

4.4. Quantification of TRPV1 Expression

The quantitative assessment of TRPV1 immunopositivity was performed in every tissue sample in the three main stomach cells: foveolar cells, parietal cells and chief cells. This quantitative assessment was based on the intensity of the immunohistochemical staining and the proportion of immunopositive cells on 10 fields of vision/slide/biopsy by an expert pathologist (A.S.) blinded to the clinical results of the initial pathology analysis (performed by H.G. and I.S.). Only the results of the quantitative assessment are reported in this study. Immunohistochemical staining density was scored on a four-point scale: no immunoreactivity (0), weak staining (1), moderate staining (2) and strong staining (3) (Table 3, A). The proportion of immunopositive cells was scored as none (0), less than 25% of the area (1), 25–49% of the area (2), 50–74% of the area (3) and more than 75% of the area (4) (Table 3, B). To summarize the quantification of TRPV1 expression in biopsies, the IRS was calculated as follows:
  • Intensity scale (A) X proportion of positive staining (B).
  • Scores were subsequently grouped to form the IRS (scale 1–12).
In addition, the IRS provides quantitative TRPV1 expression on a four-point scale: negative (0–1), slightly positive (2–3), moderately positive (4–8) and strongly positive (9–12) (Table 3, C) [47]. Tissue samples were digitalized for evaluation using a Pannoramic Digital Slide Scanner with CaseViewer software version 2.4 (3D HISTECH Ltd., Budapest, Hungary).

4.5. Data and Statistical Analysis

Statistical analysis was performed using SPSS statistics 28.0 (IBM, Armonk, NY, USA) and R version 4.4.0 (R Core Team, 2024. R: A language and environment for statistical computing. Vienna, Austria). Continuous data were presented as medians and interquartile ranges (IQRs) and categorical data as proportions (%). To compare (non-parametric) continuous data between subgroups, the Kruskal–Wallis test and post hoc Tukey’s test were conducted. To compare (non-parametric) continuous data within subgroups, a repeated measures ANOVA was conducted, including Mauchly’s Test of Sphericity, to assess the assumption of sphericity. Greenhouse–Geisser corrections were applied where necessary. Post hoc comparisons were conducted by using a paired sample t-test with Bonferroni correction for multiple testing. A P value of <0.05 was deemed statistically significant. Considering the exploratory nature of the study, no formal sample size calculation was performed.

Author Contributions

Conceptualization, D.K., Z.H. and A.A.M.M.; methodology, D.K., Z.H. and H.I.G.; software, S.R.G.; validation, D.K. and Z.Z.R.M.W.; formal analysis, S.R.G. and Z.Z.R.M.W.; investigation, Z.H., K.C. and A.S.; resources, I.S. and H.I.G.; data curation, S.R.G. and J.A.v.V.; writing—original draft preparation, S.R.G., A.M.E.A. and J.A.v.V.; writing—review and editing, S.R.G., D.K. and Z.Z.R.M.W.; visualization, S.R.G.; supervision, D.K. and Z.Z.R.M.W.; project administration, S.R.G. and J.A.v.V.; funding acquisition, Z.H. All authors have read and agreed to the published version of the manuscript.

Funding

This Project (no. TKP2021-EGA-13) has been implemented with the support provided by the National Research, Development and Innovation Fund of Hungary, financed under the EGA-13 funding scheme. RF-2.3.1-21-2022-00015 has been implemented with the support provided by the European Union.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and was evaluated and approved by the Local Ethic Committee (METC number 16-4-012) of the Maastricht University Medical Center+ (MUMC+).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data is contained within the article.

Acknowledgments

H.I.G. is supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre. All authors included have consented to the acknowledgement. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

GCgastric cancer
CAGchronic atrophic gastritis
GIMgastric intestinal metaplasia
H. pyloriHelicobacter pylori
TRPV1transient receptor potential Vanilloid 1
TRPtransient receptor potential
GIgastrointestinal
TRPMtransient receptor potential Melastin
TRPCtransient receptor potential Canonical
MUMC+Maastricht University Medical Center+
IRSimmunoreactive score

References

  1. Deng, R.; Yu, S.; Ruan, X.; Liu, H.; Zong, G.; Cheng, P.; Tao, R.; Chen, W.; Wang, A.; Zhao, Y.; et al. Capsaicin orchestrates metastasis in gastric cancer via modulating expression of TRPV1 channels and driving gut microbiota disorder. Cell Commun. Signal. 2023, 21, 364. [Google Scholar] [CrossRef] [PubMed]
  2. Kostelecka, K.; Bryliński, Ł.; Komar, O.; Michalczyk, J.; Miłosz, A.; Biłogras, J.; Woliński, F.; Forma, A.; Baj, J. An Overview of the Spices Used for the Prevention and Potential Treatment of Gastric Cancer. Cancers 2024, 16, 1611. [Google Scholar] [CrossRef]
  3. Chen, C.; Zhang, M.; Zheng, X.; Lang, H. Association between chili pepper consumption and risk of gastrointestinal-tract cancers: A meta-analysis. Front. Nutr. 2022, 9, 935865. [Google Scholar] [CrossRef]
  4. Gao, N.; Yang, F.; Chen, S.; Wan, H.; Zhao, X.; Dong, H. The role of TRPV1 ion channels in the suppression of gastric cancer development. J. Exp. Clin. Cancer Res. 2020, 39, 206. [Google Scholar] [CrossRef]
  5. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  6. Agréus, L.; Kuipers, E.J.; Kupcinskas, L.; Malfertheiner, P.; Di Mario, F.; Leja, M.; Mahachai, V.; Yaron, N.; van Oijen, M.; Perez Perez, G.; et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand. J. Gastroenterol. 2012, 47, 136–147. [Google Scholar] [CrossRef]
  7. Bacha, D.; Walha, M.; Ben Slama, S.; Ben Romdhane, H.; Bouraoui, S.; Bellil, K.; Lahmar, A. Chronic gastritis classifications. Tunis. Med. 2018, 96, 405–410. [Google Scholar]
  8. Aziz, F.; Xin, M.; Gao, Y.; Chakroborty, A.; Khan, I.; Monts, J.; Monson, K.; Bode, A.M.; Dong, Z. Induction and Prevention of Gastric Cancer with Combined Helicobacter pylori and Capsaicin Administration and DFMO Treatment, Respectively. Cancers 2020, 12, 816. [Google Scholar] [CrossRef] [PubMed]
  9. López-Carrillo, L.; Camargo, M.C.; Schneider, B.G.; Sicinschi, L.A.; Hernández-Ramírez, R.U.; Correa, P.; Cebrian, M.E. Capsaicin consumption, Helicobacter pylori CagA status and IL1B-31C>T genotypes: A host and environment interaction in gastric cancer. Food Chem. Toxicol. 2012, 50, 2118–2122. [Google Scholar] [CrossRef]
  10. Du, Y.; Lv, Y.; Zha, W.; Hong, X.; Luo, Q. Chili Consumption and Risk of Gastric Cancer: A Meta-Analysis. Nutr. Cancer 2021, 73, 45–54. [Google Scholar] [CrossRef]
  11. Szallasi, A. Capsaicin and cancer: Guilty as charged or innocent until proven guilty? Temperature 2023, 10, 35–49. [Google Scholar] [CrossRef] [PubMed]
  12. Lee, S.Y.; Masaoka, T.; Han, H.S.; Matsuzaki, J.; Hong, M.J.; Fukuhara, S.; Choi, H.S.; Suzuki, H. A prospective study on symptom generation according to spicy food intake and TRPV1 genotypes in functional dyspepsia patients. Neurogastroenterol. Motil. 2016, 28, 1401–1408. [Google Scholar] [CrossRef]
  13. Pabalan, N.; Jarjanazi, H.; Ozcelik, H. The impact of capsaicin intake on risk of developing gastric cancers: A meta-analysis. J. Gastrointest. Cancer 2014, 45, 334–341. [Google Scholar] [CrossRef] [PubMed]
  14. Trujillo Rivera, A.; Sampieri, C.L.; Morales Romero, J.; Montero, H.; Acosta Mesa, H.G.; Cruz Ramírez, N.; Novoa Del Toro, E.M.; León Córdoba, K. Risk factors associated with gastric cancer in Mexico: Education, breakfast and chili. Rev. Esp. Enferm. Dig. 2018, 110, 372–379. [Google Scholar] [CrossRef] [PubMed]
  15. Lee, I.O.; Lee, K.H.; Pyo, J.H.; Kim, J.H.; Choi, Y.J.; Lee, Y.C. Anti-inflammatory effect of capsaicin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter 2007, 12, 510–517. [Google Scholar] [CrossRef] [PubMed]
  16. Park, J.-M.; Lee, H.-J.; Yoo, J.H.; Ko, W.J.; Cho, J.Y.; Hahm, K.B. Overview of gastrointestinal cancer prevention in Asia. Best Pract. Res. Clin. Gastroenterol. 2015, 29, 855–867. [Google Scholar] [CrossRef] [PubMed]
  17. Kuzma, M.; Fodor, K.; Almási, A.; Mózsik, G.; Past, T.; Perjési, P. Toxicokinetic Study of a Gastroprotective Dose of Capsaicin by HPLC-FLD Method. Molecules 2019, 24, 2848. [Google Scholar] [CrossRef] [PubMed]
  18. Ao, Z.; Huang, Z.; Liu, H. Spicy Food and Chili Peppers and Multiple Health Outcomes: Umbrella Review. Mol. Nutr. Food Res. 2022, 66, e2200167. [Google Scholar] [CrossRef]
  19. Holzer, P. TRP channels in the digestive system. Curr. Pharm. Biotechnol. 2011, 12, 24–34. [Google Scholar] [CrossRef]
  20. Venkatachalam, K.; Montell, C. TRP channels. Annu. Rev. Biochem. 2007, 76, 387–417. [Google Scholar] [CrossRef]
  21. Kaneko, Y.; Szallasi, A. Transient receptor potential (TRP) channels: A clinical perspective. Br. J. Pharmacol. 2014, 171, 2474–2507. [Google Scholar] [CrossRef] [PubMed]
  22. Xiang, Y.; Xu, X.; Zhang, T.; Wu, X.; Fan, D.; Hu, Y.; Ding, J.; Yang, X.; Lou, J.; Du, Q.; et al. Beneficial effects of dietary capsaicin in gastrointestinal health and disease. Exp. Cell Res. 2022, 417, 113227. [Google Scholar] [CrossRef]
  23. Ward, S.M.; Bayguinov, J.; Won, K.J.; Grundy, D.; Berthoud, H.R. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J. Comp. Neurol. 2003, 465, 121–135. [Google Scholar] [CrossRef] [PubMed]
  24. Csekő, K.; Beckers, B.; Keszthelyi, D.; Helyes, Z. Role of TRPV1 and TRPA1 Ion Channels in Inflammatory Bowel Diseases: Potential Therapeutic Targets? Pharmaceuticals 2019, 12, 48. [Google Scholar] [CrossRef]
  25. Kim, H.S.; Kwon, H.J.; Kim, G.E.; Cho, M.H.; Yoon, S.Y.; Davies, A.J.; Oh, S.B.; Lee, H.; Cho, Y.K.; Joo, C.H.; et al. Attenuation of natural killer cell functions by capsaicin through a direct and TRPV1-independent mechanism. Carcinogenesis 2014, 35, 1652–1660. [Google Scholar] [CrossRef] [PubMed]
  26. Ericson, A.; Nur, E.M.; Petersson, F.; Kechagias, S. The effects of capsaicin on gastrin secretion in isolated human antral glands: Before and after ingestion of red chilli. Dig. Dis. Sci. 2009, 54, 491–498. [Google Scholar] [CrossRef] [PubMed]
  27. Dömötör, A.; Kereskay, L.; Szekeres, G.; Hunyady, B.; Szolcsányi, J.; Mózsik, G. Participation of Capsaicin-Sensitive Afferent Nerves in the Gastric Mucosa of Patients with Helicobacter pylori-Positive or-Negative Chronic Gastritis. Dig. Dis. Sci. 2007, 52, 411–417. [Google Scholar] [CrossRef] [PubMed]
  28. Basith, S.; Cui, M.; Hong, S.; Choi, S. Harnessing the Therapeutic Potential of Capsaicin and Its Analogues in Pain and Other Diseases. Molecules 2016, 21, 966. [Google Scholar] [CrossRef] [PubMed]
  29. Jiang, X.; Wang, C.; Ke, Z.; Duo, L.; Wu, T.; Wang, W.; Yang, Y.; Dai, Y. The ion channel TRPV1 gain-of-function reprograms the immune microenvironment to facilitate colorectal tumorigenesis. Cancer Lett. 2022, 527, 95–106. [Google Scholar] [CrossRef]
  30. Santoni, G.; Farfariello, V. TRP channels and cancer: New targets for diagnosis and chemotherapy. Endocr. Metab. Immune Disord. Drug Targets 2011, 11, 54–67. [Google Scholar] [CrossRef]
  31. Rooke, R. Can calcium signaling be harnessed for cancer immunotherapy? Biochim. Biophys. Acta 2014, 1843, 2334–2340. [Google Scholar] [CrossRef] [PubMed]
  32. Lo, Y.C.; Yang, Y.C.; Wu, I.C.; Kuo, F.C.; Liu, C.M.; Wang, H.W.; Kuo, C.H.; Wu, J.Y.; Wu, D.C. Capsaicin-induced cell death in a human gastric adenocarcinoma cell line. World J. Gastroenterol. 2005, 11, 6254–6257. [Google Scholar] [CrossRef] [PubMed]
  33. de Jong, P.R.; Takahashi, N.; Harris, A.R.; Lee, J.; Bertin, S.; Jeffries, J.; Jung, M.; Duong, J.; Triano, A.I.; Lee, J.; et al. Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis. J. Clin. Investig. 2014, 124, 3793–3806. [Google Scholar] [CrossRef] [PubMed]
  34. Kato, S.; Aihara, E.; Nakamura, A.; Xin, H.; Matsui, H.; Kohama, K.; Takeuchi, K. Expression of vanilloid receptors in rat gastric epithelial cells: Role in cellular protection. Biochem. Pharmacol. 2003, 66, 1115–1121. [Google Scholar] [CrossRef] [PubMed]
  35. Csekő, K.; Pécsi, D.; Kajtár, B.; Hegedűs, I.; Bollenbach, A.; Tsikas, D.; Szabó, I.L.; Szabó, S.; Helyes, Z. Upregulation of the TRPA1 Ion Channel in the Gastric Mucosa after Iodoacetamide-Induced Gastritis in Rats: A Potential New Therapeutic Target. Int. J. Mol. Sci. 2020, 21, 5591. [Google Scholar] [CrossRef] [PubMed]
  36. Bertin, S.; Aoki-Nonaka, Y.; Lee, J.; Jong, P.R.d.; Kim, P.; Han, T.; Yu, T.; To, K.; Takahashi, N.; Boland, B.S.; et al. The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1. Gut 2017, 66, 1584–1596. [Google Scholar] [CrossRef] [PubMed]
  37. Xiao, T.; Sun, M.; Kang, J.; Zhao, C. Transient Receptor Potential Vanilloid1 (TRPV1) Channel Opens Sesame of T Cell Responses and T Cell-Mediated Inflammatory Diseases. Front. Immunol. 2022, 13, 870952. [Google Scholar] [CrossRef] [PubMed]
  38. Toyoda, T.; Shi, L.; Takasu, S.; Cho, Y.M.; Kiriyama, Y.; Nishikawa, A.; Ogawa, K.; Tatematsu, M.; Tsukamoto, T. Anti-Inflammatory Effects of Capsaicin and Piperine on Helicobacter pylori-Induced Chronic Gastritis in Mongolian Gerbils. Helicobacter 2016, 21, 131–142. [Google Scholar] [CrossRef] [PubMed]
  39. Monteith, G.R.; Prevarskaya, N.; Roberts-Thomson, S.J. The calcium-cancer signalling nexus. Nat. Rev. Cancer 2017, 17, 367–380. [Google Scholar] [CrossRef]
  40. Ding, J.; Jin, Z.; Yang, X.; Lou, J.; Shan, W.; Hu, Y.; Du, Q.; Liao, Q.; Xu, J.; Xie, R. Plasma membrane Ca(2+)-permeable channels and sodium/calcium exchangers in tumorigenesis and tumor development of the upper gastrointestinal tract. Cancer Lett. 2020, 475, 14–21. [Google Scholar] [CrossRef]
  41. Xie, R.; Xu, J.; Xiao, Y.; Wu, J.; Wan, H.; Tang, B.; Liu, J.; Fan, Y.; Wang, S.; Wu, Y.; et al. Calcium Promotes Human Gastric Cancer via a Novel Coupling of Calcium-Sensing Receptor and TRPV4 Channel. Cancer Res. 2017, 77, 6499–6512. [Google Scholar] [CrossRef]
  42. Tang, B.; Wu, J.; Zhu, M.X.; Sun, X.; Liu, J.; Xie, R.; Dong, T.X.; Xiao, Y.; Carethers, J.M.; Yang, S.; et al. VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism. Oncogene 2019, 38, 3946–3961. [Google Scholar] [CrossRef] [PubMed]
  43. Almasi, S.; Sterea, A.M.; Fernando, W.; Clements, D.R.; Marcato, P.; Hoskin, D.W.; Gujar, S.; El Hiani, Y. TRPM2 ion channel promotes gastric cancer migration, invasion and tumor growth through the AKT signaling pathway. Sci. Rep. 2019, 9, 4182. [Google Scholar] [CrossRef] [PubMed]
  44. Xu, Q.; Kong, N.; Zhang, J.; Bai, N.; Bi, J.; Li, W. Expression of transient receptor potential cation channel subfamily M member 8 in gastric cancer and its clinical significance. Exp. Ther. Med. 2021, 21, 377. [Google Scholar] [CrossRef] [PubMed]
  45. Kun, J.; Helyes, Z.; Perkecz, A.; Bán, Á.; Polgár, B.; Szolcsányi, J.; Pintér, E. Effect of Surgical and Chemical Sensory Denervation on Non-neural Expression of the Transient Receptor Potential Vanilloid 1 (TRPV1) Receptors in the Rat. J. Mol. Neurosci. 2012, 48, 795–803. [Google Scholar] [CrossRef]
  46. Potolicchio, I.; Santambrogio, L.; Strominger, J.L. Molecular Interaction and Enzymatic Activity of Macrophage Migration Inhibitory Factor with Immunorelevant Peptides. J. Biol. Chem. 2003, 278, 30889–30895. [Google Scholar] [CrossRef]
  47. Fedchenko, N.; Reifenrath, J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue—A review. Diagn. Pathol. 2014, 9, 221. [Google Scholar] [CrossRef]
Ijms 25 08294 g001aIjms 25 08294 g001b
Figure 1. Microscopic pictures of gastric biopsies after immunohistochemistry. Immunohistochemical staining (TRPV1 expression) is in brown, and hematoxylin counterstain is in blue. (A,B) TRPV1 expression in gastric antral type mucosa controls (10× and 40×). (C,D) TRPV1 expression in H. pylori-associated gastritis in gastric antral type mucosa (10× and 40×). (E,F) Complete loss of TRPV1 expression in gastric adenocarcinoma antral type mucosa (10× and 40×).
Figure 1. Microscopic pictures of gastric biopsies after immunohistochemistry. Immunohistochemical staining (TRPV1 expression) is in brown, and hematoxylin counterstain is in blue. (A,B) TRPV1 expression in gastric antral type mucosa controls (10× and 40×). (C,D) TRPV1 expression in H. pylori-associated gastritis in gastric antral type mucosa (10× and 40×). (E,F) Complete loss of TRPV1 expression in gastric adenocarcinoma antral type mucosa (10× and 40×).
Ijms 25 08294 g001aIjms 25 08294 g001b
Ijms 25 08294 g002
Figure 2. Raincloud plot showing the distribution of TRPV1 expression as quantified in a median IRS: controls, H. pylori-associated gastritis with gastric intestinal metaplasia (H. pylori with GIM), chronic atrophic gastritis with GIM (CAG with GIM) and H. pylori-associated gastritis without GIM (H. pylori without GIM). The plot provides a detailed view of the distribution, central tendency and variability of TRPV1 expression (in IRS) within each group. (A) Raincloud plot of the median IRS all cells combined—showing a significantly higher TRPV1 expression in patients with GIM compared with those without GIM and controls. (B) Raincloud plot showing a significantly higher TRPV1 expression in patients with GIM compared with those without GIM and controls in parietal cells.
Figure 2. Raincloud plot showing the distribution of TRPV1 expression as quantified in a median IRS: controls, H. pylori-associated gastritis with gastric intestinal metaplasia (H. pylori with GIM), chronic atrophic gastritis with GIM (CAG with GIM) and H. pylori-associated gastritis without GIM (H. pylori without GIM). The plot provides a detailed view of the distribution, central tendency and variability of TRPV1 expression (in IRS) within each group. (A) Raincloud plot of the median IRS all cells combined—showing a significantly higher TRPV1 expression in patients with GIM compared with those without GIM and controls. (B) Raincloud plot showing a significantly higher TRPV1 expression in patients with GIM compared with those without GIM and controls in parietal cells.
Ijms 25 08294 g002
Table 1. Baseline characteristics.
Table 1. Baseline characteristics.
CharacteristicControls
(n = 5)		H. pylori with
GIM
(n = 12)		CAG with
GIM
(n = 13)		H. pylori, without GIM
(n = 19)		Gastric Adeno-
Carcinoma
(n = 6)
Age, median, years (±SD)49.60 (11.70)65.75 (10.49)57.85 (14.18)55.95 (19.25)78.33 (6.71)
<60 years, n (%)3 (60.0)3 (25.0)7 (53.8)10 (52.6)N.A.
≥60 years, n (%)2 (40.0)9 (75.0)6 (46.2)9 (47.4)6 (100)
Gender
Male, n (%)1 (20.0)6 (50.0)3 (23.1)11 (48.9)3 (50.0)
Female, n (%)4 (80.0)6 (50.0%)10 (76.9)8 (42.1)3 (50.0)
Biopsy location stomach
Antrum only, n (%)3 (60.0)2 (16.7)N.A.N.A.N.A.
Antrum and body, n (%)2 (40.0)10 (83.3)13 (100)19 (100)5 (83.3)
Other regions *, n (%)N.A.N.A.N.A.N.A.1 (16.7)
* including biopsies of cardia and angulus. Abbreviations: H. pylori = H. pylori-associated gastritis; GIM = gastric intestinal metaplasia; CAG = chronic atrophic gastritis; GC = gastric carcinoma; N.A. = not applicable.
Table 2. TRPV1 expression in median IRS.
Table 2. TRPV1 expression in median IRS.
Kruskal–Wallis Test *p-Value **
Controls
(n = 5)		H. pylori
with GIM (n = 12)		CAG
with GIM n (n = 13)		H. pylori
without GIM
(n = 19)		Gastric adeno-carcinoma
(n = 6)
TRPV1 expression in
Median IRS (±SD)
  Foveolar cellsN.A. 6.00 (3.59)5.23 (2.62)3.26 (3.08)N.A.31.10<0.001
  Parietal cells3.60 (0.54)10.25 (2.01)8.77 (1.79)6.58 (2.77)N.A.34.07<0.001
  Chief cells5.60 (2.1906.50 (2.81)6.00 (2.45)5.84 (2.14)N.A.17.680.001
  Mean IRS,
   all cells		3.07 (0.86)7.58 (1.23)6.67 (1.62)5.23 (1.88)N.A.34.73<0.001
p-Value intra-group
comparison **		0.0020.0020.0020.003N.A.
* The test statistics are adjusted for ties. ** Post hoc analysis is described in the text. Abbreviations: H. pylori = Helicobacter pylori-associated gastritis; GIM NEG = without gastric intestinal metaplasia; GIM POS = with gastric intestinal metaplasia; CAG = chronic atrophic gastritis; IRS = immunoreactive score; SD = standard deviation; N.A. = not applicable.
Table 3. Explanation and interpretation of the immunoreactive score (IRS).
Table 3. Explanation and interpretation of the immunoreactive score (IRS).
A
(Intensity Scale)		B
(Proportion of
Positive Staining in %)		IRS Score *
(Multiplication A × B)
0 = no immunoreactivity0 = no stained area0–1 = negative
1 = weak staining1 = <25% of stained area2–3 = slightly immunopositive
2 = moderate staining2 = 25–49% stained area4–8 = moderate immunopositive
3 = strong staining3 = 50–74% stained area9–12 = strongly immunopositive
4 = >75% stained area
* Final IRS score (A × B) = 0–12.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Groen, S.R.; Keszthelyi, D.; Szallasi, A.; van Veghel, J.A.; Alleleyn, A.M.E.; Csekő, K.; Helyes, Z.; Samarska, I.; Grabsch, H.I.; Masclee, A.A.M.; et al. Gastric Carcinogenesis and Potential Role of the Transient Receptor Potential Vanilloid 1 (TRPV1) Receptor: An Observational Histopathological Study. Int. J. Mol. Sci. 2024, 25, 8294. https://doi.org/10.3390/ijms25158294

AMA Style

Groen SR, Keszthelyi D, Szallasi A, van Veghel JA, Alleleyn AME, Csekő K, Helyes Z, Samarska I, Grabsch HI, Masclee AAM, et al. Gastric Carcinogenesis and Potential Role of the Transient Receptor Potential Vanilloid 1 (TRPV1) Receptor: An Observational Histopathological Study. International Journal of Molecular Sciences. 2024; 25(15):8294. https://doi.org/10.3390/ijms25158294

Chicago/Turabian Style

Groen, Sylvester R., Daniel Keszthelyi, Arpad Szallasi, Jara A. van Veghel, Annick M. E. Alleleyn, Kata Csekő, Zsuzsanna Helyes, Iryna Samarska, Heike I. Grabsch, Ad A. M. Masclee, and et al. 2024. "Gastric Carcinogenesis and Potential Role of the Transient Receptor Potential Vanilloid 1 (TRPV1) Receptor: An Observational Histopathological Study" International Journal of Molecular Sciences 25, no. 15: 8294. https://doi.org/10.3390/ijms25158294

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop